Hormone Replacement Therapy Decreases Insulin Resistance and Lipid Metabolism in Japanese Postmenopausal Women with Impaired and Normal Glucose Tolerance

2003 ◽  
Vol 60 (3) ◽  
pp. 134-142 ◽  
Author(s):  
Hiroyuki Sumino ◽  
Shuichi Ichikawa ◽  
Hiromaro Itoh ◽  
Toshihiro Utsugi ◽  
Yoshio Ohyama ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Hormone Replacement Therapy ◽  
Lipid Metabolism ◽  
Glucose Tolerance ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Normal Glucose Tolerance ◽  
Normal Glucose

Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy

Metabolism ◽  
1993 ◽  
Vol 42 (7) ◽  
pp. 846-853 ◽  
Author(s):  
Ian F. Godsland ◽  
Kevin Gangar ◽  
Christopher Walton ◽  
Michael P. Cust ◽  
Malcolm I. Whitehead ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement

INSULIN RESISTANCE AND SHORT-TERM TRANSDERMAL HORMONE REPLACEMENT THERAPY IN HYPERTENSIVE POSTMENOPAUSAL WOMEN

2000 ◽  
Vol 18 ◽  
pp. S120
Author(s):  
K. Kawecka-Jaszcz ◽  
D. Czarnecka ◽  
A. Olszanecka ◽  
A. Dembiñska-Kieç ◽  
A. Zdzienicka
Keyword(s):  
Insulin Resistance ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Short Term

Insulin resistance in postmenopausal women: concurrent effects of hormone replacement therapy and coffee

Climacteric ◽  
2008 ◽  
Vol 11 (5) ◽  
pp. 373-382 ◽  
Author(s):  
D. Catalano ◽  
G. M. Trovato ◽  
D. Spadaro ◽  
G. F. Martines ◽  
G. Garufi ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement

Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women

Metabolism ◽  
1999 ◽  
Vol 48 (9) ◽  
pp. 1193-1196 ◽  
Author(s):  
Moshe Weintraub ◽  
Itamar Grosskopf ◽  
Gideon Charach ◽  
Nachman Eckstein ◽  
Ardon Rubinstein
Keyword(s):  
Hormone Replacement Therapy ◽  
Lipid Metabolism ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Postprandial Lipid Metabolism ◽  
Postprandial Lipid

scholarly journals Effects of tibolone and cyclic hormone replacement therapy on glucose metabolism in non-diabetic obese postmenopausal women: a randomized study

2004 ◽  
pp. 705-714 ◽  
Author(s):  
LC Morin-Papunen ◽  
I Vauhkonen ◽  
A Ruokonen ◽  
JS Tapanainen ◽  
T Raudaskoski
Keyword(s):  
Insulin Secretion ◽  
Hormone Replacement Therapy ◽  
Glucose Metabolism ◽  
Glucose Tolerance ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Whole Body ◽  
C Peptide ◽  
Hepatic Insulin Extraction

OBJECTIVE AND METHODS: To study the effects of hormone replacement therapy on glucose metabolism, 31 obese (body mass index > or =27 kg/m(2)) postmenopausal women were randomized to treatment with tibolone (2.5 mg once daily; TIB; n=16) or to oestradiol valerate (2 mg daily)-dydrogesterone (20 mg daily for 2 weeks every 3 months; ED; n=15) for 12 months. Oral (OGTTs) and intravenous glucose tolerance tests (IVGTTs) and a euglycaemic hyperinsulinaemic clamp were performed before and at 6 and 12 months of treatment. RESULTS: TIB decreased the rates of whole body glucose uptake (WBGU) at 6 (P=0.04) and 12 months (P<0.001), but it did not have a significant effect on glucose tolerance. In OGTTs, serum insulin and C-peptide concentrations 2 h after the oral glucose load were increased (P<0.001 and P=0.05 respectively) at 12 months of treatment with TIB, but no changes in the areas under the curve (AUC) of insulin or C-peptide were observed. Furthermore, TIB did not have a significant effect on insulin secretion, the metabolic clearance rate (MCR) of insulin or hepatic insulin extraction. Treatment with ED did not modify the rates of WBGU, but it increased the MCR of insulin (P=0.017) and hepatic insulin extraction (P<0.001) and tended to decrease the insulin AUC (P=0.07). Moreover, glucose tolerance slightly deteriorated during this treatment (P=0.02). Although early phase insulin secretion evaluated by the serum C-peptide response at 30 min in the OGTT increased (P=0.046), the first-phase insulin response during the IVGTT decreased (P=0.05) during ED treatment. CONCLUSIONS: Despite the impairment in peripheral insulin sensitivity, TIB treatment had a neutral effect on glucose tolerance, possibly due to a compensatory decrease in endogenous glucose production. The increased demand on insulin induced by ED, due to both a stimulatory effect on pancreatic beta cells and increased insulin metabolism, may explain the slightly detrimental effect on glucose tolerance with this treatment.

scholarly journals Plasma DPP4 Activities Are Associated With Osteoporosis in Postmenopausal Women With Normal Glucose Tolerance

2015 ◽  
Vol 100 (10) ◽  
pp. 3862-3870 ◽  
Author(s):  
Tianpeng Zheng ◽  
Liuxue Yang ◽  
Yihong Liu ◽  
Hongbo Liu ◽  
Jian Yu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Insulin Resistance ◽  
Glucose Tolerance ◽  
Total Cholesterol ◽  
Postmenopausal Women ◽  
Type I Collagen ◽  
Normal Glucose Tolerance ◽  
Type I ◽  
Normal Glucose ◽  
Hs Crp

Context: Inflammation, insulin resistance, dyslipidemia, and glucagon-like peptide-1 (GLP-1) are risk factors for osteoporosis. Dipeptidyl peptidase-4 (DPP4) is a newly identified adipokine related to these risk factors. Objective: To investigate the association between plasma DPP4 activities and osteoporosis. Design, Setting, and Patients: This was a cross-sectional study conducted in Guilin, China. A total of 744 postmenopausal women with normal glucose tolerance were studied. Main Outcome Measures: Plasma DPP4 activity, inflammatory markers, blood lipids, homeostatic model assessment of insulin resistance (HOMA-IR), active GLP-1, bone turnover markers, and bone mineral density (BMD) were measured in all participants. Results: Participants in the highest quartile of DPP4 activity had higher triglyceride, total cholesterol, HOMA-IR, IL-6, high-sensitivity C-reactive protein (hs-CRP), C-terminal telopeptide of type I collagen, and osteocalcin and lower BMD (lumbar spine and femoral neck) and active GLP-1 compared with participants in the lowest quartile (P &lt; .05). DPP4 activities were associated positively with triglyceride, total cholesterol, HOMA-IR, IL-6, hs-CRP, C-terminal telopeptide of type I collagen, and osteocalcin and negatively with active GLP-1 and BMD (P &lt; .05). In the highest DPP4 quartile, osteoporosis risk was significantly higher (odds ratio, 3.01; 95% confidence interval, 1.66–5.43) than in the lowest quartile after adjustment for potential confounders. The risk for osteoporosis increased more with higher levels of DPP4 activity, HOMA-IR, IL-6, and hs-CRP (P &lt; .05), but not with higher levels of triglyceride and total cholesterol or lower levels of active GLP-1. Conclusions: This study shows that increased DPP4 activities are independently associated with osteoporosis. The mechanisms may be partly explained by the effect of DPP4 on inflammation and insulin resistance.

scholarly journals NONALCOHOLIC FATTY LIVER DISEASE IN MENOPAUSAL WOMEN

2013 ◽  
Vol 50 (3) ◽  
pp. 180-185 ◽  
Author(s):  
Gesira Soares de Assis FLORENTINO ◽  
Helma Pinchemel COTRIM ◽  
Consuelo Padilha VILAR ◽  
Andre Vinicius de Assis FLORENTINO ◽  
Geruza Maria Almeida GUIMARAES ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Hormone Replacement Therapy ◽  
Liver Disease ◽  
Fatty Liver ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Fatty Liver Disease ◽  
Hormone Replacement ◽  
Nonalcoholic Fatty Liver

Context Nonalcoholic Fatty Liver Disease (NAFLD) is common in postmenopausal women. It is associated with metabolic syndrome. However, the influence of hormone replacement therapy in NAFLD development in these women needs to be investigated. This study aimed to describe the clinical characteristics of NAFLD in postmenopausal women, and the relationship between hormone replacement therapy and this disease. Methods From April 2009 to April 2011, 292 postmenopausal women from National Health System from Northeast of Brazil were selected, and 251 were included in this study. Menopause was defined as the absence of menstruation for 12 consecutive months in otherwise healthy women. Criteria to NAFLD included: presence of steatosis on abdominal ultrasound; history of alcohol consumption less than 20 g/day and exclusion of other liver diseases. All women underwent a clinical evaluation. Standard univariate and multivariate analyses were performed to evaluate the results. Results The mean age was 56.5 ± 6.7 years. Hormone replacement therapy was referred by 21.1% (53) women and 78.9% (198) was not. Prevalence of NAFLD was 37.1% (93/251) in postmenopausal women, 26,4% (14/53) in the group with hormone replacement therapy and 39,9% (79/198) without hormone replacement therapy. Gamma-glutamyl transpeptidase (P = 0.001), alanine transaminase (P<0.01), ferritin (P<0.001) and insulin resistance (homeostatic model assessment of insulin resistance ≥3) (P<0.001) were higher in the group of women with NAFLD diagnosis who did not referred the use of hormone replacement therapy. Metabolic syndrome was also more frequent in women with NAFLD, who did not refer hormone replacement therapy. Conclusion In conclusion this data suggests elevated prevalence of NAFLD in postmenopausal women; negative association of hormone replacement therapy and NAFLD.

Sign in / Sign up

Export Citation Format

Share Document